Please provide your email address to receive an email when new articles are posted on . The FDA approved pemigatinib for treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms and ...

Genetic and Clinic of Mature Lymphoid Neoplasms has the following research output in the current window (1 October 2024 - 30 September 2025) of the Nature Index. Click on Count to view a list of ...

The Food and Drug administration has approved Pemazyre for patients with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with an FGFR1 rearrangement. The Food and Drug Administration (FDA) ...

Incyte today announced that the U.S. Food and Drug Administration has approved Pemazyre ®, a selective fibroblast growth factor receptor inhibitor, for the treatment of adults with relapsed or ...

(RTTNews) - Incyte Corp. (INCY) said that the U.S. Food and Drug Administration has approved Pemazyre (pemigatinib), a selective fibroblast growth factor receptor or FGFR inhibitor, for the treatment ...

At the recent American Society of Hematology (ASH) annual meeting, phase II data were presented on a bispecific antibody for ...

Analysis of >40 subtypes of lymphoid blood cancer tracked by the UK Haematological Malignancy Research Network reveals wide incidence and survival variation, but distinct gains in survival since ...

First-line treatment selection in follicular lymphoma is closely tied to tumor stage, disease burden, and patient-specific ...

The FDA Friday approved pemigatinib (Pemazyre), a selective fibroblast growth factor (FGFR) inhibitor, to treat adults who have relapsed or refractory (R/R) myeloid/lymphoid neoplasms (MLNs) with ...